Gian Rizzardi - MolMed S Insider

MolMed S p A -- Germany Stock  

EUR 0.43  0.02  4.88%

Director Research & Development

Dr. Gian Paolo Rizzardi serves as General Manager at Molecular Medicine S.p.A. He was Director of Research Development of Molecular Medicine S.p.A. from July 2011. He has more than 15 years experience in research on immunotherapeutic strategies, particularly in the areas of HIVAIDS and infectious diseases he contributed to the HIVAIDS field with important studies on HIV immunepathogenesis and with the design and development of immunomodulatory therapeutic strategies. Working at the Company, he also developed experience in the fields of tumor homing peptides and of vascular targeting agents. He is Author of more than 60 peerreviewed publications and, together with Mr. Giuseppe Pantaleo, won the Pfizer Prize for research in infectious diseases in 1999. He has served as University Lecturer of Internal Medicine, Immunology, Infectious Disease and Biotechnology in Italy, Switzerland and the United States. He gained a Doctorate of Medicine in Medicine from Universita degli Studi di Milano in 1991.
Age: 50  Director Since 2015  Ph.D    

Management Efficiency

The company has return on total asset (ROA) of (18.1) % which means that it has lost $18.1 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (61.21) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 964 K in total debt with debt to equity ratio (D/E) of 6.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. MolMed S p A has Current Ratio of 1.37 which is within standard range for the sector.

Similar Executives

Entity Summary

MolMed S p A (4HW) is traded on Frankfurt Stock Exchange in Germany. and employs 23 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add MolMed S p A to your portfolio

Top Management

MolMed S p Leadership Team
Gian Rizzardi, Director, Ph.D
Marina Bue, Director
Didier Trono, Director
Silvia Pisante, Executive
Mario Masciocchi, Director
Carlo Incerti, Director
Raffaella Ruggiero, Director
Holger Neecke, Director
Luca Alberici, Executive
Maurizio Tassi, Director
Daniele Pieraccioli, Director, Ph.D
Alberto Carletti, Director
Laura Ferro, Director
Marco Dieci, Director, Ph.D
Catia Traversari, Director, Ph.D
Lorenzo Salieri, Director
Elizabeth Robinson, Director
Riccardo Palmisano, CEO
Sabina Grossi, Director, Ph.D
Alfredo Messina, Director
Monica Masolo, Director
Germano Carganico, Executive, Ph.D
Claudio Bordignon, Chairman, Ph.D
Gianluigi Fiorendi, Director
Andrea Quaglino, Director
Khalid Islam, Director, Ph.D
Laura Villa, Director
Cynthia Giuliani, Director
Antonio Lambiase, Director, Ph.D
Marco Manoni, Director
Tiziano Andreoli, Director

Stock Performance

MolMed S Performance Indicators
Return On Equity(61.21) %
Return On Asset(18.1) %
Current Valuation195.6 M
Price to Earning(13.82) times
Price to Book11.53 times
Price to Sales9.28 times
Revenue22.42 M
Gross Profit1000 K
EBITDA(10.6 M)
Net Income(12.02 M)